Format

Send to

Choose Destination
Antivir Chem Chemother. 2014 Jan 29;23(4):145-9. doi: 10.3851/IMP2551.

Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.

Author information

1
Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Abstract

Persistence of HIV-1 in latently infected CD4(+) T-cells prevents eradication in HIV-infected treated patients. Latency is characterized by a reversible silencing of transcription of integrated HIV-1. Several molecular mechanisms have been described which contribute to latency, including the establishment and maintenance of repressive chromatin on the HIV-1 promoter. Histone deacetylation is a landmark modification associated with transcriptional repression of the HIV-1 promoter and inhibition of histone deacetylase enzymes (HDACs) reactivates latent HIV-1. Here, we review the different HDAC inhibitors that have been studied in HIV-1 latency and their therapeutic potential in reactivating latent HIV-1.

PMID:
24318952
PMCID:
PMC3947511
DOI:
10.3851/IMP2551
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center